Sequenom and Cypher Genomics have struck a development agreement for noninvasive prenatal testing, the companies said today. Sequenom will use Cypher’s genome interpretation technology, Mantis, to analyze clinically relevant fetal sub-chromosomal variants detected in maternal blood.
Sub-chromosomal variants are often not detected until after birth and they make up more than 50 percent of rare chromosomal abnormalities beyond the more common aneuploidies and are associated with morbidity and mortality risks.
Prenatal Information Research Consortium 